Author's response to reviews

Title: P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients

Authors:

Ruoping Tang (ruoping.tang@htd.aphp.fr)
Simy Cohen (simyalice@yahoo.fr)
Jean-Yves Perrot (jean-yves.perrot@htd.aphp.fr)
Anne-Marie Faussat (Anne-Marie.Faussat@ifr58.bhdc.jussieu.fr)
Claudia Zuany-Amorim (Claudia.Fromond@sanofi-aventis.com)
Zora Marjanovic (zora.marjanovic@htd.aphp.fr)
Hamid Morjani (hamid.morjani@univ-reims.fr)
Ollivier Legrand (ollivier.legrand@htd.aphp.fr)
Jean-Pierre Marie (jean-pierre.marie@htd.aphp.fr)
Elise Corre (corre.elise@yahoo.fr)
Fanny Fava (fava.fanny@yahoo.fr)

Version: 3 Date: 31 March 2009

Author's response to reviews: see over
Dear Editor,

We would like to resubmit our revised manuscript “P-gp activity is a critical resistance factor against AVE9633 and DM4 cytotoxicity in leukaemia cell lines, but not a major mechanism of chemoresistance in cells from acute myeloid leukaemia patients” to BMC Cancer (MS: 3838860542207331).

First, we would like to thank the Referees on their comments, and the effort invested to help us to express our results unequivocally, and in that way improve our paper. Following the remarks of the Referees, we have once again reviewed our manuscript, and below you will find our reply and corrections point by point.

**Point by point responses to Referee 1, Dr. Edward D Ball:**

What is “LAM”? Is this meant to be the FAB nomenclature? Note that patient 21 has the translocation found in promyelocytic leukaemia, which is M3, not M1. Also, that patient was said to have a WBC of 139.7 which is quite high for this subtype. They should check the data on this patient.

**Responses:**

Many thanks for the serious review of the referee. LAM is AML in French. We are very sorry to make this mistake. We have modified the table, for the FAB subtype, we have changed LAM1 on M1, LAM2 on M2, LAM4 on M4……
For patient 21, we have made a mistake when we copied and pasted the data from our database. This patient is M1 with normal karyotype. We have modified this point. Once more sorry for this mistake.

Thanks again the referee. We hope that we have correctly replied the referee, and that he has convinced by our responses. This revision allows us to improve this manuscript.

Sincerely yours,

Dr Ruoping TANG